Invalidity dossier
US 12419895
Added 4/30/2026, 3:10:54 PM
⚖️ Active PTAB challenge: 1 pending proceeding against this patent
1 active — Inter Partes Review, Post-Grant Review, or Covered Business Method proceedings at the USPTO Patent Trial and Appeal Board.
Got a demand letter citing US 12419895?
Paste the full letter into the analyzer. We extract every asserted patent (this one and any others), characterize the asserter, flag validity vulnerabilities, and draft a sample response letter your attorney can adapt.
Generic sample response letter (PDF)
Generates a draft reply letter to a generic infringement claim citing this patent, using the analysis below. For a response tailored to a specific letter you received, use the demand letter analyzer instead. Sample only — not legal advice. Do not send without review by a licensed patent attorney.
Watchlist
Get alerted when this patent moves.
Email-only, free, anonymous. We'll notify you when US 12419895 gets a new lawsuit, a new PTAB proceeding, or a new dossier section. One-click unsubscribe from any alert.
Active provider: Google · gemini-2.5-pro
Auto-generating section 1 of 2: PTAB challenges…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Summary of U.S. Patent 12,419,895
A concise summary of U.S. Patent 12,419,895 is provided below, based on the authoritative patent text and public records as of April 30, 2026.
Title: Methods for treating subjects with Prader-Willi syndrome
Assignee: Essentialis Inc.
Inventor: Neil M. Cowen
Filing Date: May 30, 2025
Issue Date: September 23, 2025
Abstract:
The patent describes pharmaceutical formulations of potassium ATP (K-ATP) channel openers and their use, either alone or in combination with growth hormone, for treating various diseases and conditions, including Prader-Willi Syndrome (PWS) and Smith-Magenis syndrome (SMS).
Plain-Language Overview of Independent Claims:
This patent contains several independent claims directed at methods of treating specific symptoms in subjects with Prader-Willi Syndrome (PWS). The core of the invention is the administration of a K-ATP channel opener, a type of drug that affects cellular activity.
Claim 1: This claim outlines a method for increasing the lean body mass in a person with PWS. It involves administering an effective amount of a K-ATP channel opener for at least four weeks. The treatment can optionally be combined with growth hormone. The claim specifies that the lean body mass should increase by at least 1%.
Claim 8: This claim focuses on reducing hyperphagia (excessive hunger and food consumption) in a PWS subject. The method involves administering a K-ATP channel opener, optionally with growth hormone, for at least four weeks. The goal is to reduce hyperphagia by at least 10%.
Claim 12: This claim details a method for reducing body fat in an individual with PWS. It requires administering a K-ATP channel opener, again with the option of adding growth hormone, for a minimum of four weeks to achieve at least a 1% reduction in body fat.
Claim 16: This claim describes a method for treating a PWS patient who is already receiving growth hormone therapy. The method involves co-administering a K-ATP channel opener to increase their lean body mass.
Claim 17: Similar to the previous claim, this claim addresses a PWS patient already being treated with a K-ATP channel opener. The method involves adding growth hormone treatment to increase the patient's lean body mass.
There is no information available from the CAFC 2026 dockets regarding this patent. All information is based on the provided patent text.
Generated 4/30/2026, 3:12:34 PM